Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression

INCLUSION CRITERIA * Patient (and legally designed representative of minor patient) able to correctly understand the trial and to sign the informed consent * Aged ≥ 15 years * Confirmed HIV-1 infection as documented at any time prior to trial entry per national HIV testing procedures * CD4 count ≤ 100 cells/μL * Hospitalized for a newly diagnosed TB, defined by: * Any positive Xpert® MTB/RIF specimen (sputum, urine, pus, other), * Or a positive urine lipoarabinomannan (LAM) test, * Or an abnormal chest X-ray compatible with active TB EXCLUSION CRITERA * Initiation of TB drugs for more than 7 days * History of TB treatment during the last 6 months * Central neurological symptoms, including but not restrictive to TB meningitis * Suspected TB pericarditis * Documented Mycobacterium tuberculosis strain resistant to rifampicin using rapid molecular testing (Xpert® MTB/RIF) * Any concomitant medication or known hypersensitivity contraindicating any component of the TB treatment * HIV-2 co-infection * Current treatment with ART containing protease inhibitors * Any contraindication to efavirenz and dolutegravir * Severe associated diseases requiring corticosteroids or for which corticosteroids are contra-indicated * Impaired hepatic function with ALT (SGPT) \> 5 times the upper limit of normal (ULN) value * Creatinine clearance \< 30 mL/min/1.73m2 (according to either the MDRD or the CKD-EPI formula) * Pregnancy or breastfeeding